

**FEATURED SPEAKERS**



**Klaus Lindpaintner**  
Head, Medical Genomics; VP, Research, Roche

**Giora Feuerstein**  
AVP & Head Discovery, Translational Medicine, Wyeth



**Nicholas C. Dracopoli**  
VP, Biomarkers Centocor, Johnson & Johnson

**David Wholley**,  
Director, Biomarkers Consortium, Foundation for the NIH



**Lawrence J. Lesko**  
Director, Clinical Pharmacology CDER, FDA

**C. Thomas Caskey**  
EVP, Molecular Medicine and Genetics, Univ. of Texas Health Science Center



**Geert Kolvenbag**  
Global Product VP, Oncology, AstraZeneca



**Robert S. Epstein**  
SVP & Chief Medical Officer, Medco Health Solutions

**Phil Hewitt**  
Head, Molecular Toxicology, Merck



 Cambridge Healthtech Institute  
250 First Avenue, Suite 300  
Needham, Massachusetts 02494  
Telephone: 781-972-5400  
Toll-free in the U.S. 888-999-6288  
Fax: 781-972-5425  
www.healthtech.com

**REGISTER BY FEBRUARY 27, 2009 AND SAVE UP TO \$500**



Cambridge Healthtech Institute's Fifth Annual

# BIOMARKER WORLD CONGRESS 2009



May 27-29, 2009 | Loews Philadelphia Hotel | Philadelphia, Pennsylvania

**PRE-CONFERENCE EVENTS:**

- Executive ThinkTank: Collaborations, Consortia, and Funding Opportunities in Biomarker Development
- Short Course: Fit-for-Purpose Biomarker Assay Development & Validation
- Workshop: Biomarkers for Cancer Drug Development

**COMPREHENSIVE COVERAGE OF BIOMARKERS IN:**

- Personalized Medicine
- Clinical Pharmacology
- Translational Medicine
- Molecular Diagnostics
- Safety Assessment
- Clinical Trials
- Assay Development
- Biomarker Qualification
- Oncology Drugs & Diagnostics

PART OF:

 **Biomarkers and DIAGNOSTICS SERIES**

**CORPORATE SPONSORS:**



**CORPORATE SUPPORT SPONSORS:**



**LEAD SPONSORING PUBLICATIONS:**



**www.BiomarkerWorldCongress.com**

# HOTEL & TRAVEL INFORMATION

## HOTEL

Loews Philadelphia Hotel  
1200 Market Street  
Philadelphia, PA 19107  
Phone: 215-627-1200  
Fax: 215-231-7205

Discounted Room Rate: \$209 s/d  
Reduced Room Rate Cutoff: May 6, 2009

To reserve your hotel room, please call the hotel directly. Identify yourself as a Cambridge Healthtech Institute conference attendee to receive the reduced room rate. Reservations made after the cut-off date or after the group room block has been filled (whichever comes first) will be accepted on a space-and-rate-availability basis. Rooms are limited, so please book early.

## Flight Discounts:

To receive a 5% discount on American Airlines, American Eagle and AmericanConnections call and make your flight reservations at 1-800-433-1790 or go online at aa.com.

Please refer to the authorization number AN# A2418SS via phone or enter it in the promotion discount box online.

## Car Rental Discounts:

Special discount rentals have been established with AVIS for this conference. Call AVIS directly at 800-331-1600 and reference your Avis Worldwide Discount (AWD) Number J868190.

# PRESENT A POSTER

Reasons You Should Present Your Research Poster at THE BIOMARKER WORLD CONGRESS:

- Your poster will be exposed to over 400 delegates
- Receive \$50 off your registration fee
- Your poster abstract will be published on our conference CD
- Your research will be seen by leaders from top pharmaceutical, biotech, academic and government institutes

**NEW!**

# BIOMARKER WEB SYMPOSIA

Please join us for live interactive web symposia from the comfort of your office and learn about cutting-edge biomarker research and strategies. No costs or hassles of travel, no time away from the office!

Visit [www.BiomarkerWebinars.com](http://www.BiomarkerWebinars.com) for more info.

## DISTINGUISHED FACULTY:

John Allinson, FIBMS, Laboratory Director,  
Veeda Clinical Research

Stewart Bates, Ph.D., Director, Stevenage Core  
Technologies Group, Discovery  
Technology Group, GlaxoSmithKline

John C. Bloom, V.M.D., Ph.D., Executive  
Director, Diagnostic & Experimental  
Medicine, Eli Lilly & Co.

Michael E. Burczynski, Ph.D., Associate  
Director, Biomarker Lab, Clinical Translational  
Medicine, Wyeth Pharmaceuticals

Marci Copeland, Research Scientist, Monarch  
LifeSciences

Maryellen de Mars, Ph.D., Director, Clinical  
Biomarkers, The Critical Path Institute

Viswanath Devanarayan, Ph.D., Director,  
Statistics, Biomarker Research, Abbott  
Laboratories

Nicholas C. Dracopoli, Ph.D., Vice President,  
Biomarkers, Centocor Research &  
Development, Johnson & Johnson

Robert E. Epstein, M.D., M.S., Senior Vice  
President, Medical & Analytical Affairs; Chief  
Medical Officer, Medco Health Solutions, Inc.

Giora Feuerstein, M.D., Assistant Vice  
President & Head, Discovery Translational  
Medicine, Wyeth Research

Paul J. Fielder, Ph.D., Senior Director  
& Senior Scientist, Early Development  
Pharmacokinetics, Pharmacodynamic and  
Bioanalytical Sciences, Genentech, Inc.

Mark Fidock, Ph.D., Head, Biochemical and  
Molecular BioMarkers, Experimental Biological  
Sciences, Pfizer Limited

Dorothee Foernzler, Ph.D., Biomarker-  
Experimental Medicine Leader,  
F. Hoffmann-La Roche AG

Alberto Gutierrez, Ph.D., Deputy Director,  
Office of In Vitro Diagnostic Device Evaluation  
and Safety (OIVD), U.S. Food  
and Drug Administration

Yiwu He, Ph.D., Senior Program Officer,  
Global Health Discovery, Bill & Melinda Gates  
Foundation

Phil Hewitt, Ph.D., Head, Molecular Toxicology,  
Institute of Toxicology, Merck KGaA

Darren Hodgson, Ph.D., Biomics Advisor,  
OncologyTherapy Area, AstraZeneca

Arthur L. Holden, Ph.D., Chairman and Chief  
Executive Officer, International Serious  
Adverse Event Consortium, Ltd. (SAEC)

Martina Kaufmann, Ph.D., Biomarker Project  
Leader, Head OBI Basel, Oncology Biomarker  
& Clinical Imaging, Novartis Pharma AG

Geert Kolvenbag, M.D., Ph.D., Global Product  
Vice President, Oncology, AstraZeneca  
Pharmaceuticals, Inc.

Kwan R. Lee, Ph.D., Senior Director,  
Biomarkers and Predictive Analytics, Drug  
Development Science, GlaxoSmithKline  
Pharmaceuticals R&D

Lawrence J. Lesko, Ph.D., F.C.P., Director,  
Office of Clinical Pharmacology, Center for  
Drug Evaluation and Research, U.S. Food and  
Drug Administration

Klaus Lindpaintner, M.D., M.P.H., Head,  
Medical Genomics & Vice President, Research,  
F. Hoffmann-La Roche AG

Helen M. Moore, Ph.D., Director, Biospecimen  
Research Network, National Cancer Institute,  
National Institutes of Health

Scott D. Patterson, Ph.D., Executive Director,  
Medical Sciences, Amgen, Inc.

Wendy Sanhai, Ph.D., Senior Scientific Advisor,  
Office of the Commissioner, U.S. Food and  
Drug Administration

Yaping Shou, M.D., Ph.D., Director,  
Oncology Biomarkers and Imaging, Novartis  
Pharmaceuticals

Brian B. Spear, Ph.D., Director, Scientific  
Affairs, Global Pharmaceutical Research and  
Development, Abbott Labs

Craig Stovold, Ph.D., Senior Analytical Project  
Manager, Bioanalytical Sciences, Quotient  
BioResearch

Linda C. Surh, M.D., Ph.D., FRCPC,  
Director, CEDD Global Regulatory Affairs,  
Neurosciences and Pharmacogenetics,  
GlaxoSmithKline, UK

Christine Tavano, Ph.D., Field Application  
Scientist, Ingenuity Systems

Shikha Varma-O'Brien, Ph.D.,  
Associate Director, Life Sciences, Accelrys

Ole Vesterqvist, Ph.D., Senior Director,  
Biomarker Lab & Outsourcing, Clinical  
Translational Medicine, Wyeth Research

Xinkang Wang, Ph.D., Head, Imaging  
Biomarker Group, Discovery Translational  
Medicine, Wyeth Research

Jeffrey Waring, Ph.D., Associate Research  
Fellow & Group Leader, Cellular & Molecular  
Toxicology, Abbott Labs

David Wholley, Director, Biomarkers  
Consortium, Foundation for the National  
Institutes of Health

Hans Winkler, Ph.D., Senior Director & Global  
Head, Oncology Biomarkers, Pharmaceutical  
Research & Development, Johnson & Johnson

## CONFERENCE-AT-A-GLANCE

Wednesday, May 27	
7:30 -12:00	Registration for Pre-Conference Events
8:00-11:00	Pre-Conference Workshop <i>(Separate Registration Required)</i> <b>Biomarkers for Cancer Drug Development</b>
12:00-3:00	Pre-Conference Short Course <i>(Separate Registration Required)</i> <b>Fit-For-Purpose Biomarker Assay Development and Validation</b>
12:00-3:00	Executive ThinkTank <i>(Premium Package Registration Required)</i> <b>Collaborations, Consortia, and Funding Opportunities in Biomarker Development</b>
3:00-4:00	Conference Registration
4:00-5:15	Plenary Keynotes
5:15-6:30	Opening Reception in the Exhibit Hall <span style="float: right;"><i>Sponsored by</i> </span>
Thursday, May 28	
7:00	Registration Open
7:30-8:15	Breakfast Presentation <span style="float: right;"><i>Sponsored by</i> </span>
8:25-9:30	<b>Delivering on the Promise of Personalized Medicine</b>
9:30-10:30	Networking Coffee Break with Poster and Exhibit Viewing
10:30-12:00	TECHNOLOGY SHOWCASE I: <b>Biomarkers in Early Drug Development</b> TECHNOLOGY SHOWCASE II: <b>Biomarkers in Clinical Development and Diagnostics</b>
12:00-1:00	Lunch on your own
1:00-2:30	<b>Implementing Personalized Medicine</b> <b>Biomarker Adoption in Clinical Trials</b>
2:30-3:30	Networking Refreshment Break with Poster and Exhibit Viewing
3:30-5:30	<b>Molecular Diagnostics for Personalized Medicine</b> <b>Clinical Pharmacology</b>
Friday, May 29	
7:00	Registration Open
7:30-8:25	Breakfast Presentation <i>(Opportunity Available)</i>
8:25-9:30	<b>Biomarkers in Translational Medicine</b>
9:30-10:30	2:30-3:30 Networking Refreshment Break with Poster and Exhibit Viewing <span style="float: right;"><i>Sponsored by</i> </span>
10:30-12:30	<b>Toxicity Biomarkers</b> <b>Biomarker Assay Development</b>
12:30-2:00	<b>Luncheon Presentation</b> <span style="float: right;"><i>Sponsored by</i> </span> <b>Luncheon Presentation</b> <span style="float: right;"><i>Sponsored by</i> </span>
2:00-4:00	<b>Biomarker Qualification: Biological and Analytical Validation</b>
4:00	Close of Conference

### Sponsoring Publications:



### Web Partners:



[www.BiomarkerWorldCongress.com](http://www.BiomarkerWorldCongress.com)

## SPONSORSHIPS & EXHIBITS

### Sponsorship Opportunities

Brand your company as a thought leader in the global biomarker community by participating as an active Sponsor. Showcasing your technologies, services and solutions to our highly targeted audience can significantly impact their buying decisions and help you achieve your sales and business development objectives.

### OPPORTUNITIES INCLUDE:

#### User Group Meetings

Co-locate your user group meeting with The Biomarker World Congress. CHI will help market the event, manage logistical operations, develop the agenda, and more. CHI can handle the entirety of the meeting, or aspects of your choosing.

#### Agenda Presentations

Speak to a captive audience about your latest technology. This sponsorship includes a 15 or 30 minute podium presentation within the scientific agenda as well as exhibit space, onsite branding and access to cooperative marketing efforts by CHI.

#### Breakfast Workshops

These presentations include a 30-minute podium presentation with a 15-minute Q&A session. Invite session attendees to enjoy breakfast on your company's behalf while you give your talk.

#### Invitation-Only VIP Dinner

Sponsor will hand pick its top prospectus for a night of networking at a top local venue. To ensure optimum face-to-face networking, CHI suggests dinner be limited to 20 guests, including invited guests, three representatives from sponsoring company and one or two representatives from Cambridge Healthtech Institute. CHI will work closely with Sponsor to develop an invitation format and invite list.

#### Focus Groups

CHI will gladly provide you the opportunity of running a focus group on-site at the Biomarker World Congress. This exclusive gathering can be useful to conduct market research, gather feedback on a new product idea and gather marketing intelligence from industry experts on a specific topic.

#### Promotional Opportunities

- Branded Tote Bags distributed to all conference delegates
- Chair Drop of company literature
- Branded Badge Lanyards distributed to all conference delegates
- Conference Padfolios
- Tote Bag Inserts of company literature

#### Exhibiting

Exhibiting allows your company to differentiate your technologies, services or solutions from competitors and demonstrate its commitment to this science. Exhibitors will enjoy facilitated networking opportunities with 400+ qualified delegates, making it a perfect platform to launch a new product, collect feedback and generate new leads.

For more information, please contact:

**Ilana Schwartz**

Manager, Business Development

781-972-5457 | [ischwartz@healthtech.com](mailto:ischwartz@healthtech.com)

**Wednesday, May 27****7:30-12:00 Registration for Pre-Conference Events****8:00-11:00 Pre-Conference Workshop\* (\*Separate Registration Required)****Biomarkers for Cancer Drug Development****8:00 Chairperson's Opening Remarks***Nicholas C. Dracopoli, Ph.D., Vice President, Biomarkers, Centocor Research & Development, Johnson & Johnson***8:00-8:30 Measuring the Impact of Biomarkers in Cancer Drug Development***Nicholas C. Dracopoli, Ph.D., Vice President, Biomarkers, Centocor Research & Development, Johnson & Johnson*

A recent survey of oncology drugs entering clinical development showed that the attrition rate of molecularly targeted therapies is approximately one third of the rate for all oncology drugs. These data support the idea that greater scientific understanding of a drug target and its biological pathway will lead to lower attrition rates in drug development. This presentation will review the recent impact of biomarkers in confirming mechanism of action in preclinical models, exploring PK/PD interactions and defining Phase II dose, and in developing companion diagnostics to predict drug efficacy for novel oncology therapies. The presentation will also discuss why more companion diagnostics have not been developed, and argue that molecular pathological techniques to provide direct readouts of the functional status of drug targets and downstream pathways remain essential for the development of companion diagnostics for new targeted oncology therapies.

**8:30-9:00 Biomarkers for Anti-Angiogenic Drugs – A Long Way to Go?***Dorothee Foerzler, Ph.D., Biomarker-Experimental Medicine Leader, F Hoffmann-La Roche AG*

This presentation will examine the relevance of biomarkers for anti-angiogenic therapies in oncology, and discuss status of biomarkers in angiogenesis and evaluation of personalized health care opportunities. I will also discuss biomarker strategy - asking the right questions and using the appropriate technologies to develop biomarkers for anti-angiogenic therapies in oncology, and implementation of the biomarker strategy. This is where the hard work starts: challenges and experiences.

**9:00-9:30 Imaging Biomarkers in Oncology in Drug Discovery and Development***Xinkang Wang, Ph.D., Head, Imaging Biomarker Group, Discovery Translational Medicine, Wyeth Research*

Abstract unavailable at the time of printing.

**9:30-10:00 Networking Coffee Break****10:00-10:30 Oncology Drug Development: Letting Biomarkers Lead the Way***Martina Kaufmann, Ph.D., Biomarker Project Leader, Head OBI Basel, Oncology Biomarker & Clinical Imaging, Novartis Pharma AG*

Oncology is leading the way in exploiting molecular biological and genetic information to develop personalized medicine. Biomarkers are pivotal for optimization of dose and schedule, prediction of patients that will respond, rapid detection of tumor response in proof-of-concept trials, use of surrogate endpoints for disease monitoring, assuring safety of drug therapy and development of rational-based combination therapies. A general strategy for use of biomarkers to accelerate oncology drug development will be presented.

**10:30-11:00 Title to be Announced***Kurtis E. Bachman, Ph.D., Director; Head, Translational Medicine, Cancer Metabolism, Cancer Research, Oncology R&D, GlaxoSmithKline*

Abstract unavailable at the time of printing.

**11:00 Close of Pre-Conference Short Course****12:00-3:00 Pre-Conference Short Course\* (\*Separate Registration Required)****Fit-For-Purpose Biomarker Assay Development and Validation***John Allinson, FIBMS, Laboratory Director, Veeda Clinical Research*

This tutorial will provide recommendations on the "fit-for-purpose" best practices in the development and validation of biomarker assays for the intended exploratory or advanced biomarker applications. Strategies for different applications at various phases of biomarker development will be described. Key elements in the method of development and validation will be illustrated with examples, including reference to standard material, sample stability and collection integrity, validation and QC samples, validity of reference standards, calibration curve fitting methods, method optimization and feasibility studies. The special challenges in protein biomarker assays will be discussed, including strategies for moving from biomarker panels in the exploratory phase to the few markers chosen to support clinical trials.

*Viswanath Devanarayan, Ph.D., Director, Statistics, Biomarker Research, Abbott Laboratories*

This tutorial will provide recommendations on the "fit-for-purpose" best practices in the development and validation of biomarker assays for the intended exploratory or advanced biomarker applications. Strategies for different applications at various phases of biomarker development will be described. Key elements in method development and validation will be illustrated with examples, including reference to standard material, sample stability and collection integrity, validation and QC samples, validity of reference standards, calibration curve fitting methods, method optimization and method feasibility studies. The special challenges in protein biomarker assays will be discussed, including strategies for moving from biomarker panels in the exploratory phase to the few markers chosen to support clinical trials.

Outline:

1. Introduction - Nomenclature, types of biomarker methods/assays, biomarker method development & validation road map, fundamental validity, similarity and differences from PK assays & diagnostic application.
2. Pre-analytical and Bioanalytical elements: Target range, standards, validation & QC samples, stability, matrix effect, specificity, and relative selectivity.
3. Calibration curve model selection, evaluation, and weighting.
4. Method feasibility and optimization with precision profiles.
5. Evaluation of some pre-study validation characteristics such as precision, bias, sensitivity and quantification limits.
6. Use of Sample Controls for in-study performance monitoring and conformance testing among laboratories.

Please visit [www.BiomarkerWorldCongress.com](http://www.BiomarkerWorldCongress.com) for course outline.**12:00-3:00 Executive ThinkTank\* (\*Premium Package Registration Required)****Collaborations, Consortia, and Funding Opportunities in Biomarker Development****12:00 Chairperson's Opening Remarks***Phillips Kuhl, President, Cambridge Healthtech Institute***12:00-12:30 Participant Introductions****12:30-12:50 The Role of Public-Private Partnerships in Driving Biomarker Development: The Biomarkers Consortium***David Wholley, Director, Biomarkers Consortium, Foundation for the National Institutes of Health*

Launched in November 2006, the Biomarkers Consortium has experienced both substantial progress and substantial change over the last 12 months. Mr. Wholley, who has served as director of the Consortium since March 2008, will describe how public-private partnerships generally, and the Consortium in particular, are playing a key role in the development and qualification of biomarkers with particular relevance for more efficient and effective development of therapeutics and personalized medicine.

**12:50-1:10 The Serious Adverse Event Consortium, Ltd. (SAEC): Formation and Current Status of an International Effort to Understand the Genetic Basis of Drug Related Serious Adverse Events***Arthur L. Holden, Ph.D., Chairman and Chief Executive Officer, International Serious Adverse Event Consortium, Ltd. (SAEC)*

The Serious Adverse Event Consortium (SAEC) has been formed to identify and validate DNA-variants useful in predicting the risk of drug induced serious adverse events [SAEs]. It is a nonprofit organization comprised of leading international pharmaceutical companies, and academic institutions with scientific and strategic input from the U.S. Food and Drug Administration (FDA). This presentation will summarize the origins and current status of this novel research initiative, its current research methods, results to date and potential new solutions for more efficient and effective SAE research. The SAEC's initial studies will focus on identifying genetic markers associated with drug-related liver toxicity [DILI] and serious skin rash [SSR]. The SAEC will collect SAE samples and data from the participating pharmaceutical companies and academic institutions. These well-characterized cases will be compared with control cases to identify genetic variants that may be associated with these SAEs. The identification of these genetic variations is believed to be essential to develop safer drugs while also identifying patient populations at risk. The SAEC is exploring partnerships with international private and government institutions to better conduct their research.

**1:10-1:30 Biomarker Discovery in Global Health***Yiwu He, Ph.D., Senior Program Officer, Global Health Discovery, Bill & Melinda Gates Foundation*

There is an unprecedented need for the development of new drugs/vaccines, diagnostics, and prevention strategies to ease the impact of the infectious diseases such as AIDS, TB, and malaria. Biomarkers hold great promise to identify risk for disease, to make a diagnosis, to assess severity of disease and to guide treatment. Biomarkers can also be used in research and clinical studies to assess drug efficacy and safety. The presentation will provide an overview of biomarker discovery needs in global health area and explore potential collaborating opportunities.

**1:30-3:00 Discussion with all Participants**

**Wednesday, May 27**


**3:00-4:00 Conference Registration**  
**4:00-4:15 Welcoming Remarks from Conference Director**  
*Julia Boguslavsky, Cambridge Healthtech Institute*

**Plenary Keynotes**

**4:15-4:45 Predictive Biomarkers: Using What's Been Learned from Past Regulatory Decisions to Inform Future Development Plans**  
*Lawrence J. Lesko, Ph.D., F.C.P., Director, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration*  
 Biomarker discovery and qualification remains a complex issue in the drug development and approval process. There is an intuitive sense that biomarker-driven decisions can have a positive effect on productivity and diagnostic tests can stratify patients into subgroups with different benefit/risk ratios. Thus, looking at past research examples can provide a solid foundation for future biomarker development strategies. One key and very basic question is: what does experience with biomarker development tell us about the differences between their use in efficacy, safety and dosing?

**4:45-5:15 Opening Reception in the Exhibit Hall** *Sponsored by* 

**Thursday, May 28**

**7:00 Registration Open**  
**7:30-8:15 Breakfast Presentation: In-Depth Analysis of Protein Biomarkers in FFPE Tissue** *Sponsored by*   
*David Krizman, Ph.D., Chief Scientific Officer and Co-founder, Expression Pathology Inc.*

The LiquidTissue® protocol makes it possible to analyze proteins in FFPE tissue. The technology can be used to discover and validate differentially expressed protein biomarkers in FFPE tissue. This opens new opportunities in companion diagnostics, prognostic biomarkers, and drug targets. The technology also has potential in drug development, clinical trials and personalized medicine. It can be used to quantify protein expression in standard patient samples and provide diagnostic and prognostic information to guide treatment decisions.

**Delivering on the Promise of Personalized Medicine**

**8:25-8:30 Chairperson's Opening Remarks**  
**8:30-9:00 Biomarkers in Personalized Health Care: Opportunities, Challenges, Approaches**  
*Klaus Lindpaintner, M.D., M.P.H., Head, Medical Genomics & Vice President, Research, F Hoffmann-La Roche AG*

The discussion about the application of biomarkers to more targeted treatment addresses fundamentally the issues of a better understanding of inter-individual differences in drug response that are independent of particular disease states, as well as a molecular rewriting of the textbook of medicine. The latter is aimed at a more differentiated, basic concept of disease mechanisms which may then allow a shift from the current largely empiric and palliative to a causally targeted pharmacopoeia. However, the associated expense to health care systems will need to be justified by demonstration of appropriate clinical utility, in the sense of incremental cost-efficacy ratios. This will require a systematic, staged, and case-specifically adjusted approach for optimal balance of risk-benefit, and ultimate sustainable success of the concept.





**9:00-9:30 Personalized Medicine: Turning Promise into Reality**  
*Geert Kolvenbag, M.D., Ph.D., Global Product Vice President, Oncology, AstraZeneca Pharmaceuticals, Inc.*

The promise of personalized medicine is emerging from theoretical discussions for practical applications in cancer care. With a few successful examples already in the clinic, the challenges for developing new personalized medicine approaches have not decreased. In contrast, new and higher hurdles for clinical and biomarker development and approval have appeared in the last few years. A case report will be presented on a new approach, currently in phase II clinical development, highlighting these hurdles and potential approaches to address them.

**9:30-10:30 Networking Coffee Break with Poster and Exhibit Viewing**

**TECHNOLOGY SHOWCASE I:**

**TECHNOLOGY SHOWCASE II:**

<b>Biomarkers in Early Drug Development</b>	<b>Biomarkers in Clinical Development and Diagnostics</b>
<p><b>10:30-10:45 Finding Evidence for Drug-Induced Cholestasis Biomarkers, A Knowledge Profile Approach</b> <i>Sponsored by</i> </p> <p><i>Ilya A. Mazo, Ph.D., President, Ariadne, Inc.</i></p> <p>Using the proprietary high-content linguistics tool MedScan®, a database of knowledge profiles associated with different diseases and small molecule effects has been compiled by extracting biological facts and relationships from scientific literature. Systematic mining of this database, ChemEffect™, for knowledge on existing drugs/drug candidates garnered from published findings can help in hypothesizing a mechanism behind drug-induced cholestasis. This analysis workflow often leads to identifying potential biomarker candidates, backed with supporting scientific evidence from other studies. In this talk, different approaches to develop mechanistic models from the ChemEffect™ knowledgebase and from microarray data will be described.</p>	<p><b>10:30-10:45 Multiplexed Assays for High-Throughput Biomarker Analysis</b> <i>Sponsored by</i> </p> <p><i>Craig Stovold, Ph.D., Senior Analytical Project Manager, Bioanalytical Sciences, Quotient Bioresearch</i></p> <p>The increasing importance of biomarkers to support clinical studies and pharmaceutical licensing provides a number of challenges for the analytical laboratory. An extensive panel of biomarkers is desirable to fully characterise a disease state and drug efficacy, often limited by ethical considerations and the requirement for clinical safety testing. Quotient Bioresearch provide a number of multiplexing methods, including LC-MS/MS for small and large molecules, Meso-Scale Discovery, and Gyrolab®, increasing the throughput of biomarker analysis giving determination of a greater number of analytes, from a smaller sample in a reduced time frame.</p>
<p><b>10:45-11:00 Identification of Master-Regulators of Adverse Toxic Reactions of the Antibiotic Drug Trovafloxacin (TVX) through Promoter Analysis and Network Modeling</b> <i>Sponsored by</i> </p> <p><i>Alexander Kel, Ph.D., Senior Vice President Research &amp; Development, BIOBASE GmbH</i></p> <p>In this talk, we will present a case study of applying the BIOBASE Knowledge Library™ and the Explain™ Analysis Platform for discovery of drug toxicity biomarkers. We analyzed data on the antibiotic drug trovafloxacin (TVX), which was recently removed from the market because of severe idiosyncratic hepatotoxic side effects. The aim of this study was to find molecular mechanisms of adverse drug reactions and identification of potential causal biomarkers for patient stratification. Expression profiles of primary human hepatocytes treated with trovafloxacin were analysed through Explain™ performing promoter analysis of differentially expressed genes followed by topological modeling of signal transduction networks. We predicted the following transcription factors, which are involved in coordinated deregulation of genes upon treatment with TVX: HNF1α, HNF4, AhR/ARNT, ELK1 and others. Topological modeling of respective transcription regulatory and signal transduction networks allowed us to identify master-regulators of the toxic reactions in liver cells and propose perspective causal biomarkers of liver toxicity of trovafloxacin.</p>	<p><b>10:45-11:00 Current Information Trends in Biomarker Research</b> <i>Sponsored by</i> </p> <p><i>Colin Williams, Ph.D., Product Manager, Biology &amp; Bioinformatics, Thomson Reuters</i></p> <p>Biomarkers are becoming a key tool in enhancing the productivity of pharmaceutical research &amp; development, both in discovery and the clinic and an essential element for regulatory purposes. It will become increasingly difficult to manage the rapidly increasing information about a biomarker. A new fully indexed biomarker database, BIOMARKERcenter, will help to address this problem. Using BIOMARKERcenter we will show how biomarkers mimic the lifecycle of a drug, from discovery to approval, and show the diversity of roles and techniques currently being employed in biomarker research.</p>

**11:00-11:30 Prioritization of Biomarker Candidates Based on Pathway and Phenotype Associations** *Sponsored by*

*Christine Tavano, Ph.D., Field Application Scientist, Ingenuity Systems*



As technologies that detect transcripts, microRNA levels, and epigenetic events mature to become common components of biomarker discovery programs, the challenge has shifted to translating large scale datasets into biomarkers that can be used to diagnose disease and predict patient response to treatment. Prioritization of biomarker candidates requires – at a very practical level – an understanding of candidates’ expression patterns in bodily fluids and target tissues and – at the mechanistic level – identification of molecular paths between candidate markers and physiological responses, cellular phenotypes, or disease processes of interest. In this session we will present a case study in which the biomarker discovery tool IPA was used to prioritize biomarker candidates and elucidate the molecular mechanisms connecting those markers to disease phenotypes and pathways.

**11:30-11:45 Advances in xMAP Technology: Optimized Multiplex Biomarker Assessment** *Sponsored by*

*Sean M. Higgins, Ph.D., Senior Field Marketing Scientist, Luminex Corp.*



**11:45-12:00 Unlocking Biomarker Knowledge in Public and Proprietary Experimental Data** *Sponsored by*

*James Flynn, Ph.D., Field Application Scientist, NextBio*



The development of novel Biomarkers holds great promise to improve upon current clinical attrition rates. In this presentation we will demonstrate how the NextBio platform can be used to unlock the biomarker data within public and proprietary genomic data, semantically link knowledge sources, and stimulate hypotheses generation and validation. The NextBio platform allows you to validate hypotheses in biological terms that every scientist understands and before experiments and clinical trials are run, thereby improving the success of experiments.

**11:00-11:30 In Situ Multiparametric Analysis of Biomarkers In Heterogeneous FFPE Tissue Using the Definiens XD™ Image Analysis Platform** *Sponsored by*

*Peter A. Duncan, Director, Marketing and Business Development Life Sciences, Definiens Inc.*



Although we are now beginning to benefit from the genetic, genomic, and proteomic discoveries over the last decade, the implementation of biomarkers for patient stratification to improve diagnostics, prognostics, and companion assays for oncology targeted therapies is still an extremely challenging endeavor with limited success. This is due to many factors including the lack of implementation of true systems-based approaches to achieve in situ multiplexed, multiparametric, phenotypic profiling of protein biomarkers. This talk will illustrate how this challenge is currently being met utilizing the Definiens XD image analysis platform, citing specific examples including: The automation of the Dako Herceptest, and the development of a multivariate model for overall survival of non-small cell lung cancer patients treated with Iressa®. Applications of the Definiens XD image analysis platform to xenograft detection and 3D in vivo imaging will also be presented.

**11:30-11:45 The Use of Biomarkers in Global Clinical Trials** *Sponsored by*

*Maribeth Raines, Ph.D., Director, Scientific Affairs, Quest Diagnostics*



As biomarkers become more critical in drug development studies, their prevalence in global clinical trials has increased. The challenges of supporting biomarker testing for global clinical studies will be discussed in the context of how it influences biomarker development and validation as well as strategies for deploying and standardizing biomarker testing worldwide.

**12:00-1:00 Lunch on your own**

**Implementing Personalized Medicine**

**1:00 Chairperson’s Opening Remarks**  
*Chairperson to be Announced*

**1:00-1:30 Promulgating use of Pharmacogenomics Tests on a National Level: The Medco Experience**

*Robert E. Epstein, M.D., M.S., Senior Vice President, Medical & Analytical Affairs; Chief Medical Officer, Medco Health Solutions, Inc.*  
This session will cover experience to date of a pharmacy benefit manager ‘rolling out’ programs that promulgate the use of pharmacogenomic tests. From data gleaned from actual experience with programs that address both Tamoxifen and Warfarin pharmacogenomics, payer concerns, results of actual physician and member adoption, ability of test values to change treatment decisions, and other practical issues will be shared. Opportunities for improvement to the healthcare system to facilitate greater adoption will be suggested.

**1:30-2:00 A Business Context for Personalized Medicine Research & Development**

*Brian B. Spear, Ph.D., Director, Scientific Affairs, Global Pharmaceutical Research and Development, Abbott Labs*  
Targeting new medicines to specific patients is an attractive concept commercially as well as medically. However, not all new drugs will be suited to this approach. Whether a personalized medicine strategy is appropriate for any specific drug will depend on, among other things, the nature of the disease, variability in patient response, the competitive environment, and the availability of biomarkers for patient categorization. The presentation will describe criteria useful in assessing the likelihood of success in the development and commercialization of a targeted or personalized medicine.

**2:00-2:30 Biostatistics Challenges in Personalized Medicine**

*Kwan R. Lee, Ph.D., Senior Director, Biomarkers and Predictive Analytics, Drug Development Science, GlaxoSmithKline Pharmaceuticals R&D*  
Personalized medicine is the delivery of the right drug, at the right dose, for the right patient, at the right time. In theory, personalized medicine is the management of a patient’s disease or disease predisposition, by using molecular analysis to achieve the optimal medical outcomes for that individual – thereby improving the quality of life and health, and potentially reducing overall healthcare costs. In practice, personalized medicine is a comprehensive approach utilizing molecular analysis of both patients and healthy individuals to guide decisions throughout all stages of the discovery and development of pharmaceuticals and diagnostics. It involves application of this knowledge in clinical practice for a more efficient delivery of accurate and quality healthcare through improved prevention, diagnosis, treatment, and monitoring methods. Pharmacogenomics is the science that allows us to predict a response to drugs based on an individual’s genetic makeup (genome and expression of genes) and it is the major contributor to the theory and practice of personalized medicine. In this talk we will briefly review the important biostatistics component of Pharmacogenomics. Topics will include design and analysis of ‘omics data and reliable diagnostic algorithm development. We will also discuss biomarker based targeted clinical trials, and early biomarker development in oncology drug discovery and how pharmacogenomics allows us to project the information to clinical development.

**Biomarker Adoption in Clinical Trials**

**1:00 Chairperson’s Opening Remarks**  
*Hans Winkler, Ph.D., Senior Director & Global Head, Oncology Biomarkers, Pharmaceutical Research & Development, Johnson & Johnson*

**1:00-1:30 Considerations on the Level of Evidence for Biomarker Adoption**

*Scott D. Patterson, Ph.D., Executive Director, Medical Sciences, Amgen, Inc.*  
Patient stratification biomarkers would ideally be implemented prior to randomization of pivotal trials, but this may not always occur due to a sufficient understanding of the mechanisms of resistance to therapy being elucidated later in the clinical trial process rather than early. The various factors one needs to consider will be presented through example in this presentation.

**1:30-2:00 Biomarkers in Drug Development Compared to Medical Practice: Overlaps, Gaps, and Flaps**

*Linda C. Surh, M.D., Ph.D., FRCP, Director, CEDD Global Regulatory Affairs, Neurosciences and Pharmacogenetics, GlaxoSmithKline, UK*  
The context in which emerging biomarkers are used is critical, so that appropriate decision-making can be made in the face of limited resources whether in industry, government or medicine. This presentation will attempt to take an emerging biomarker beyond the ‘what is the technology and why do it’ to ‘what is the clinical relevance and where to do it.’ Using pharmacogenomics (PGx) as an example of an emerging biomarker, it is evident that with assay capabilities more widely understood, it is now important to address the challenges of clinical interpretations in different situations. Thus, depending on the pipeline phase, how do innovative biomarkers integrate so as to aid in the progression of new medicines which are timely, effective, and safe.

**2:00-2:30 Use of a Surrogate Biomarker as an Efficacy Endpoint in Clinical Trials and a Monitoring Tool in Routine Patient Management**

*Yaping Shou, M.D., Ph.D., Director, Oncology Biomarkers and Imaging, Novartis Pharmaceuticals*  
The presentation will discuss the definition and qualification criteria of surrogate endpoints and as a case study, describe the development of blood BCR-ABL transcripts as a surrogate endpoint in CML. The technical challenges and regulatory considerations will be discussed in the implementation of this surrogate endpoint in clinical drug development and routine clinical practice.

**2:30-3:30 Networking Refreshment Break with Poster and Exhibit Viewing** *Sponsored by*



Molecular Diagnostics for Personalized Medicine	Clinical Pharmacology
<p><b>3:30-4:00 Predictive Biomarkers in Clinical Development</b>  <i>Darren Hodgson, Ph.D., Biomics Advisor, Oncology Therapy Area, AstraZeneca</i>            When, how and why can one develop a new predictive biomarker in parallel to a candidate drug? In this talk we will discuss the requirements of assays, human samples, data and trials needed in order to develop diagnostic pre-cursors and the decision making data required to justify investing in a co-development program.</p>	<p><b>3:30-4:00 Application of Pharmacodynamic Markers for Proof of Principle</b>  <i>Hans Winkler, Ph.D., Senior Director &amp; Global Head, Oncology Biomarkers, Pharmaceutical Research &amp; Development, Johnson &amp; Johnson</i>            Novel targeted therapeutics are expected to improve the treatment of cancer. However, they are expected to be effective in only a subpopulation of any tumor type. It is therefore of prime importance to identify these tumors up front and select patients for treatment based on predictive markers. Before major investments in such a strategy are warranted, the value of a compound needs to be assessed thoroughly. Demonstration in the clinic of adequate target modulation (Proof of Principle) is critical for progressing compounds to efficacy analyses. Examples of clinical pharmacodynamic results, opportunities and pitfalls will be discussed.</p>
<p><b>4:00-4:30 Strategies for Companion Diagnostic Development in a Pharmaceutical Research &amp; Development Setting</b>  <i>John C. Bloom, V.M.D., Ph.D., Executive Director, Diagnostic &amp; Experimental Medicine, Eli Lilly &amp; Co.</i>            The development and commercialization of novel diagnostics that enhance the value of drugs to patients, payers and prescribers is increasingly critical to "personalizing" medicines and differentiating new drugs in the marketplace. Strategies for building the capability to address such anticipated and unforeseen opportunities entail understanding the regulatory process and options for approval; and ensuring access to the appropriate specimens required for development, intellectual property rights and mutually profitable business partnerships. This presentation will review the challenges that building the required virtual technical and process diagnostic development expertise entail in today's rapidly changing Research &amp; Development environment.</p>	<p><b>4:00-4:30 Translational Pharmacology: Using PD-Biomarkers and PK/PD Modeling to Bridge Preclinical and Clinical Pharmacology</b>  <i>Paul J. Fielder, Ph.D., Senior Director &amp; Senior Scientist, Early Development Pharmacokinetics, Pharmacodynamic and Bioanalytical Sciences, Genentech, Inc.</i>            The development of novel biological therapies is a complex and dynamic process, which involves the interplay between the pharmacology and biology of both the disease target and the biology of the therapeutic. These unique complexities can impact molecule selection, preclinical testing strategies, development of clinical plans, and help inform second generation molecules. Translational pharmacology is an approach which combines data from preclinical efficacy studies and knowledge about the clinical target and uses PD-biomarkers and PK/PD modeling to help inform the development path. A major focus will be on how to use these novel approaches to inform key decision points during the development process and to inform second generation molecules.</p>
<p><b>4:30-5:00 Regulatory Perspective of the Role of <i>In Vitro</i> Diagnostics in Personalized Medicine</b>  <i>Alberto Gutierrez, Ph.D., Deputy Director, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD), U.S. Food and Drug Administration</i>  <i>In Vitro</i> Diagnostics are medical devices. FDA regulation is science-based and involves an overlapping series of well-defined but flexible pre-market and post-market controls. Personalized medicine has placed the diagnostic in center stage, since the safety and effectiveness of therapeutic decisions are dependent on a single diagnostic. The regulatory challenges presented by this prominent role will be discussed.</p>	<p><b>4:30-5:00 Developing Biomarkers for Proof-of-Pharmacology</b>  <i>Mark Fidock, Ph.D., Head, Biochemical and Molecular BioMarkers, Experimental Biological Sciences, Pfizer Limited</i>            The presentation will describe the utilization of biomarkers in early clinical drug development. This will focus on developing techniques to successfully identify molecules or processes that have changed in response to therapeutic treatment to deliver accurate decision making data. It will include a case study of assays for immune modulation in pre-clinical species and in man.</p>
<p>5:00 Close of Day</p>	



## Insight Pharma Reports

Expert Intelligence for Better Decisions

## Cancer Biomarkers: Adoption is Driving Growth

This new report offers in-depth analysis of:

- The current cancer biomarker products, applications, and markets
- Key validation and assessment cancer biomarker programs integrating established "standards of care" for cancer diagnosis and treatment
- Product opportunities for improved screening and early detection, to provide better guidance on therapy, for understanding cancer staging, response to treatment, and prognosis
- Profile of business models behind cancer biomarker products and a SWOT analysis associated with specific strategies
- Projections for market growth for cancer biomarker product categories

Visit our website for full details: [www.InsightPharmaReports.com](http://www.InsightPharmaReports.com)

- 7:00 Registration Open**
- 7:30-8:25 Breakfast Presentation** (Opportunity Available. Contact Ilana Schwartz at 781-972-5457 or ischwartz@healthtech.com.)

## Biomarkers in Translational Medicine

- 8:25-8:30 Chairperson's Opening Remarks**
- 8:30-9:00 Translational Medicine in the Pharmaceutical Industry: Addressing Multiple Challenges in the New Environment**

*Giora Feuerstein, M.D., Assistant Vice President & Head, Discovery Translational Medicine, Wyeth Research*

The pharmaceutical industry is facing tremendous new challenges in innovative drug discovery and development. These include translation and validation of large genetic/genomic databases into disease relevant targets, unprecedented pharmacovigilance in safety and tolerability, personalized medicine needs, regulatory policy makers, and patient advocacy group and payers' needs. Translational medicine in the pharmaceutical industry is a new entity within research & development that aligns and integrates discovery, pre-clinical development and clinical development to optimize success in meeting the new environment challenges. Specific illustrations on how translational medicine solves problems will be discussed.

- 9:00-9:30 Biomarkers in Translational Medicine: Importance of Technological and Operational Innovation**

*Michael E. Burczynski, Ph.D., Head, Biomarker Lab, Clinical Translational Medicine, Wyeth Pharmaceuticals*

The primary role of translational medicine in drug development is to support decision-making through the use of biomarkers and experimental studies in humans. This presentation will discuss the importance of both technological and operational innovations in translational medicine. It will provide some concrete examples of innovative technologies such as the Singulex Erenna™ technology, mass spectrometry and multiplexed assay platforms. The presentation will also discuss the importance of operational innovation and how it can significantly impact the use of biomarkers in the development process.

- 9:30-10:30 Networking Coffee Break with Poster and Exhibit Viewing**

Toxicity Biomarkers		Biomarker Assay Development	
<b>10:30 Chairperson's Opening Remarks</b>	<i>Jeffrey Waring, Ph.D., Associate Research Fellow &amp; Group Leader, Cellular &amp; Molecular Toxicology, Abbott Labs</i>	<b>10:30 Chairperson's Opening Remarks</b>	<i>Michael E. Burczynski, Ph.D., Head, Biomarker Lab, Clinical Translational Medicine, Wyeth Research</i>
<b>10:30-11:00 Predictive Safety Biomarkers in Non-Clinical Development</b>	<i>Phil Hewitt, Ph.D., Head, Molecular Toxicology, Institute of Toxicology, Merck KGaA</i> This presentation will examine the benefits of safety biomarkers as decision making tools, current predictive safety biomarkers, and assessing the impact of toxicogenomics. It will consider the question: Can we predict hepatotoxicity using gene expression changes in primary hepatocytes? And, finally, will discuss combining 'omics technologies with traditional toxicology endpoints: a unique strategy for toxicity prediction and mechanistic elucidation.	<b>10:30-11:00 The Critical Role of Characterizing Emerging Technologies Prior to Biomarker Development</b>	<i>Cynthia S. Spittle, Ph.D., Senior Research Scientist &amp; Head, Pharmacogenomics, Biomarker Lab, Clinical Translational Medicine, Wyeth Research</i> Novel technologies enabling more specific and highly sensitive assays for detection and/or quantitation of biomarkers are constantly emerging. While the benefits of such instrumentation advances are clearly evident, a thorough understanding of the molecular principles (and limitations) by which these biomarker detection technologies work is required. Careful characterization and analytical validation of these platforms is a critical first step prior to generating data that will assist in biomarker-driven decision making in clinical development.
<b>11:00-11:30 Identification of Proteasome Gene Regulation in a Rat Model for Hyperlipidemia using Microarray Analysis</b>	<i>Jeffrey Waring, Ph.D., Associate Research Fellow &amp; Group Leader, Cellular &amp; Molecular Toxicology, Abbott Labs</i> Elevations in serum triglycerides and cholesterol can be an adverse effect associated with some classes of new drug candidates. Identifying candidates in these drug classes that are not associated with dyslipidemia has been hindered by the lack of mechanistic information and the unavailability of relevant animal models. The present study evaluated the potential use of gene expression changes in rat liver in the development of an exploratory hyperlipidemia model.	<b>11:00-11:30 Discovery of Serum/Plasma Biomarkers for the Early Detection of Ovarian Cancer: Issues and Approaches</b>	<i>Patrick M. Sluss, Ph.D., Director, Special Chemistry Core Laboratories, Massachusetts General Hospital, Associate Professor, Harvard Medical School</i> <div style="text-align: right; font-size: small;">Sponsored by </div>
<b>11:30-12:00 Finding Biomarkers that Predict Rare Adverse Events: Assessing the Risk for Acute Idiosyncratic Hepatocellular Injury (AIHI)</b>	<i>John C. Bloom, V.M.D., Ph.D., Executive Director, Diagnostic &amp; Experimental Medicine, Eli Lilly &amp; Co.</i> Finding biomarkers that predict rare idiosyncratic adverse events has been problematic for many reasons. This has been particularly true for hepatotoxicity, or Acute Idiosyncratic Hepatocellular Injury (AIHI), which is the adverse event that most frequently leads to regulatory action on drugs, including failure to approve, post-marketing warnings added to the label and withdrawal from the market. Additional biomarkers are needed to enable more effective risk assessment and management of AIHI, including markers for identifying candidate drugs with this toxic potential and patients at risk or predisposed to AIHI, and for early detection and management of patients affected in clinical trials and practice. Approaches to the discovery and validation of such markers were reviewed in a recent meeting jointly sponsored by the Food and Drug Administration, the Pharmaceutical Research and Manufacturers of America, and the American Association for the Study of Liver Diseases; and in a recent Institute of Medicine Forum on Assessing and Accelerating the Development of Biomarkers for Drug Safety. This presentation will review the options that were identified for finding clinical biomarkers that predict AIHI, based on our current understanding of the mechanisms of this toxicity and the clinical populations at risk, and the research proposals that emerged from these discussions.	<b>11:30-12:00 Fit-for-Purpose Assay Validation in the Protein Biomarker Pipeline</b>	<i>Richard C. Jones, Ph.D., Head, Mass Spectrometry, NextGen Sciences, Inc.</i> <div style="text-align: right; font-size: small;">Sponsored by </div> The ability to generate putative protein biomarkers increases every year with improved discovery platforms in multiple disciplines. However, a major bottleneck has been the ability to develop assays in an acceptable timeframe in order to begin to validate putative biomarkers and move the viable biomarker candidates forward. Multiplexed mass spectrometry based assays are of considerable interest as they offer a potential solution to the biomarker validation problem. Using a multiplexed mass spectrometry platform it is possible to significantly shorten assay development time relative to other more conventional platforms such as immuno-affinity based methods. This allows resources to be focused on the utility of the putative biomarker and not on the development of the assay. Depending on the application, the level of bioanalytical assay validation may be tailored such that it is fit for a given purpose. In early biomarker discovery stages, minimal validation is required but as the usefulness of a single biomarker or a panel of multiple biomarkers is more clearly defined, the level of assay validation increases. Here, we will discuss several example assays and outline the level of validation deemed fit-for-purpose in their application.

<p><b>12:00-12:30 Speaker to be Announced</b></p>	<p><b>12:00-12:30 Meso Scale Discovery's Multiplexed Assays for Safety and Toxicology Assays</b> <i>Sponsored by</i> </p> <p><i>Pankaj Oberoi, Ph.D., Director, Qualified Kit Development, Meso Scale Discovery</i></p> <p>Traditional clinical markers for organ toxicity are not always sensitive enough to detect subtle damage and histopathology is not amenable to high enough throughput for preclinical studies. Meso Scale Discovery (MSD) has an electrochemiluminescence platform that is fast (1-3 minutes per plate independent of plate density), robust (non-fluidics instrument), radioactive free, sensitive (detection limits near 10 attomoles) and has a wide dynamic range (5 logs) with multiplexing capabilities. MSD has developed several multiplex panels for traditional and emerging safety biomarkers for kidney, cardiac, muscle, vascular, and liver damage. This talk will discuss assay development challenges (critical reagent characterization, specificity, abundance of biomarkers, and matrix interaction) encountered during development of Qualified kits used in preclinical and clinical studies.</p>
---	---

<p><b>12:30-2:00 Luncheon Presentation</b> <i>Sponsored by</i> </p> <p><b>Biomarker Discovery, Validation and Implementation for Drug Development and Commercialization</b></p> <p><i>Daniel Chelsky, Ph.D., Chief Scientific Officer, Caprion Proteomics</i></p> <p>Caprion Proteomics and Covance have teamed up to provide a full biomarker service, including pre-clinical and clinical studies, biomarker discovery and validation, as well as assay development and implementation.</p>	<p><b>12:30-2:00 Luncheon Presentation</b> <i>Sponsored by</i> </p> <p><b>Use of Mass Spectrometry-Based Protein Assays for Sensitive and Selective Analysis of Biomarkers in Preclinical and Clinical Efficacy and Physiology Models</b></p> <p><i>Marci Copeland, Research Scientist, Monarch LifeSciences</i></p> <p>Biomarkers for use in preclinical animal models and clinical applications can be instrumental in studying disease physiology and drug efficacy. Often sensitive and selective antibodies and subsequent immune or radioimmunoassays, are unavailable. Additionally, in cases where isoforms of a protein or modifications of a protein require discrimination, a reagent based assay might be impractical or subject to poor selectivity. In these instances a mass-spectrometry (MS) based assay may be a viable and sensitive alternative. We will discuss the development of several highly sensitive, high-throughput mass spectrometry-based assays for use in preclinical and clinical analysis or biomarkers. One assay for P1NP from rat plasma or serum that does not rely on antibody reagents and a second assay for human Alcohol Dehydrogenase (ADH) which distinguishes the various isoforms in liver tissue will be discussed in detail. Sample preparation considerations, development of sensitive and selective MS-based assays, and absolute quantification methodology will be discussed. P1NP immunoassay data will be compared to MS-based P1NP data to access reproducibility. In addition to absolute selectivity, the MS-based assays provide throughput parallel to that of most antibody-based assays so they can handle a large number of samples that are generated from preclinical animal studies.</p>
--	--

## Biomarker Qualification: Biological and Analytical Validation

**2:00 Chairperson's Opening Remarks**

*Chairperson to be Announced*

**2:00-2:30 Biomarker Development and their Clinical Qualification**

*Wendy Sanhai, Ph.D., Senior Scientific Advisor, Office of the Commissioner, U.S. Food and Drug Administration*

A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. In this regard, the spectrum of uses for biomarkers ranges from diagnostic tools (early identifiers of disease, target identification), patient identification/triage (e.g. Her-2-Nu positive for treatments with Herceptin), tools in assessing response to therapy (mechanistic biomarkers and imaging modalities) and biomarkers that are used for staging disease progression. This presentation will describe some of the biomarker development efforts underway at FDA and in partnership with FDA, and will list some of the benefits obtained to date.

**2:30-3:00 Critical Path Institute: Collaboration Towards Biomarker Qualification**

*Maryellen de Mars, Ph.D., Director, Clinical Biomarkers, The Critical Path Institute*

Critical Path Institute creates innovative collaborations in research and education that enable the safe acceleration of the process for developing new medical products. One particular area of focus for C-Path-led efforts is the development of biomarkers and qualification for use in assessing drug safety and drug efficacy. Ongoing projects in cancer (efficacy) and cardiovascular (safety) biomarkers will be highlighted. The aim of these collaborative efforts is to help define and streamline a process for developing qualified biomarkers and to standardize the evaluation and validation of molecular diagnostics.

**3:00-3:30 Biospecimen Research to Enable Molecular Medicine**

*Helen M. Moore, Ph.D., Director, Biospecimen Research Network, National Cancer Institute, National Institutes of Health*

Biospecimens, such as tissue, blood or urine, are routinely collected to aid in patient diagnosis and disease research. Notably, biospecimens are vulnerable to environmental and biological stresses introduced by routine collection, processing, storage, and transport procedures prior to analysis. These "pre-analytical" variables may transform the molecular profile of the biospecimen before it ever reaches the clinician or researcher. Without proper understanding of the impact of pre-analytical variables, molecular changes may be misinterpreted as disease-related or even disease-specific findings. New attention to this issue is needed, particularly with the movement toward an era of "Personalized Medicine," where appropriate preservation of biospecimens will be essential for molecular tests that diagnose disease and target therapies based on patient molecular characteristics. The National Cancer Institute has recently established a new research program, "The Biospecimen Research Network," to improve the quality of biospecimen-based research by sponsoring, conducting, and collaborating on research studies to assess the effects of human specimen pre-analytical variables on the outcome of genomic and proteomic studies. These results will support discovery efforts and contribute to the development of evidence-based best practices for the collection, processing, storage, and analysis of biospecimens, building on the "NCI Best Practices for Biospecimen Resources."

**3:30-4:00 RNA Readouts as Clinical Biomarkers**

*Stewart Bates, Ph.D., Director, Stevenage Core Technologies Group, Discovery Technology Group, GlaxoSmithKline*

RNA profiling technologies provide an opportunity for unbiased biomarker discovery, and recent years have seen a significant increase in the translation of these RNA-based endpoints in clinically utility. We have used RNA profiling to identify candidate pharmacological and diagnostic biomarkers across a range of applications in preclinical and clinical drug discovery. In particular, coupling the use of RNA profiling to *ex vivo* human cell and tissue models, we have not only been able to identify candidate gene signatures, but also translate these findings into clinically validated biomarkers. I will discuss some examples of both diagnostic and pharmacological biomarkers that we have validated through this translational model.

**4:00 Close of Conference**

## PARTICIPATING COMPANIES IN 2008

Abbott Bioresearch Center, Inc.  
Abbott Labs  
Ablynx  
Abpro Labs  
Academia Sinica  
Aderans Research Institute  
Affymetrix  
American College of Radiology  
Amgen, Inc.  
Amylin Pharmaceuticals, Inc.  
Analytical Biological Services  
Aperio Technologies, Inc.  
ApoConsult LLC  
Ariadne Genomics, Inc.  
Assay Designs, Inc.  
Astellas Pharma, Inc.  
Asterand  
AstraZeneca  
Pharmaceuticals, Inc.  
AstraZeneca R&D Sodertalje  
Asubio Pharma  
Asuragen, Inc.  
Aureon Labs  
Aushon BioSystems, Inc.  
Aviir, Inc.  
Axela Biosensors  
Battelle Memorial Institute  
Bayer AG  
Bayer Schering Pharma AG  
BCM Technologies, Inc.  
bigtec Private Ltd.  
Bill & Melinda Gates Foundation  
Bio Rad Labs  
BIO Ventures for Global Health  
BioAtla  
BIOBASE Corp.  
BioFortis, Inc.  
Biogen Idec, Inc.  
BioMarker Associates, Inc.  
Biomeasure, Inc.  
Biomedical Diagnostics  
BioMS Medical Corp.  
BioPorto AS  
Bioscan, Inc.  
BioServe  
Biotech  
Biotrin International  
BioTrove, Inc.  
Biovica AB  
BRAHMS USA  
Brendan Technologies, Inc.  
Bristol Myers Squibb Co.  
British American Tobacco  
Caprion Proteomics  
Cardiome Pharma  
CCC Diagnostics LLC  
Celera Diagnostics  
Centocor R&D, Inc.  
Central Connecticut State Univ.  
CentraLabS Clinical Research  
Charles River Labs  
Childrens Hospital of Philadelphia  
Cirion Central Lab  
ClinXus  
Covance Labs  
Covance Research Products  
Critical Path Institute  
Current BioData, Ltd.  
CXR Biosciences  
Daiichi Sankyo Co., Ltd.  
Debiopharm SA  
Decision Biomarkers, Inc.  
Decision Resources, Inc.  
DiaGenic ASA  
DiagnoCure, Inc.

Digna Biotech  
DOCRO  
Echelon Biosciences, Inc.  
Ege University  
Elan Pharmaceuticals  
Eli Lilly & Co.  
EMD Serono  
Emerging Growth Equities, Ltd.  
Epigenomics, Inc.  
Eppendorf Biochip Systems GmbH  
Eurofins Medinet  
Eurofins Scientific, Inc.  
Exagen Diagnostics  
Exiqon AS  
Expression Analysis, Inc.  
Expression Pathology, Inc.  
F. Hoffmann-La Roche AG  
F. Hoffmann-La Roche, Inc.  
Food & Drug Administration (FDA)  
FDA CDRH  
FDA NCTR  
Foundation for the NIH  
Fraunhofer Institute of Toxicology & Experimental Medicine  
Fred Hutchinson Cancer Research Center  
Fujifilm Medical Systems USA  
Gaiker Technological Center  
Ganymed Pharmaceuticals  
Gedeon Richter, Ltd.  
Geisinger Medical Center  
Gen Probe, Inc.  
Gene Express, Inc.  
GeneNews, Inc.  
Genentech, Inc.  
Genetic Engineering News  
Genetix USA, Inc.  
Genizon Biosciences, Inc.  
Genomic Health, Inc.  
Genoptix, Inc.  
Gentel Biosciences, Inc.  
GenWay Biotech, Inc.  
Geron Corp.  
GlaxoSmithKline  
GlaxoSmithKline Biologicals  
Growing Company Solutions, Inc.  
GVK Biosciences PVT, Ltd.  
Gyros US  
Hadasit, Ltd.  
Health Canada  
Heinrich Heine Univ.  
Duesseldorf  
HFL, Ltd.  
Hills Pet Nutrition  
HistoRx Inc  
Huntingdon Life Sciences  
HVA, Inc.  
ICON Labs  
Indivumed, Inc.  
Industrial Technology Research Institute  
Ingenuity Systems, Inc.  
Innogenetics, Inc.  
Innogenetics NV  
INSERM  
Institut Curie  
Institut Pasteur  
Institut Servier  
International Institute for the Advancement of Medicine  
Intrinsic Life Sciences  
Invitrogen  
IO Informatics, Inc.  
IVM Mongolia  
Jean Brown Research

Johns Hopkins Univ.  
Johnson & Johnson  
Pharmaceutical R&D  
Juvenile Diabetes Research Foundation  
King Saud Univ.  
Lee Pharm  
LifeSensors, Inc.  
Lilly Singapore Center for Drug Discovery  
Luminex Corp.  
Luminex Molecular Diagnostics, Ltd.  
Macedonian Academy of Sciences & Arts  
Mayo Clinic  
Mayo Collaborative Services  
M.D. Anderson Cancer Center  
Medical College of Georgia  
MedImmune, Inc.  
Medtronic Sofamor Danek  
Merck & Co.  
Merck Research Labs  
Merck Serono  
Meso Scale Discovery  
Metabolon, Inc.  
Metanomics Health GmbH  
Midwest Research Institute  
Millennium  
Pharmaceuticals, Inc.  
Millipore Corp.  
Miraculins Inc  
Mitsubishi Pharma Co.  
Mitsubishi Tanabe Pharma Corp.  
Monarch LifeSciences  
Myriad Genetics, Inc.  
National Cancer Institute  
National Research Council Canada  
National Univ. of Singapore  
Nerviano Medical Sciences  
New York Univ.  
NextGen Sciences, Ltd.  
NIBSC  
National Institutes of Health  
NIH Korea Center for Disease Control  
Novartis Pharma AG  
Novartis Pharmaceuticals  
Novo Nordisk  
NuGEN Technologies, Inc.  
OncoMethylome Sciences, Inc.  
Onconome, Inc.  
Open Biosystems, Inc.  
Ortho Clinical Diagnostics, Inc.  
OSI Pharmaceuticals  
Oxford Gene Technology  
Pacific Biometrics, Inc.  
Palau Pharma  
Pathway Diagnostics  
Personalized Medicine Partners LLC  
Pfizer Global R&D Groton Labs  
Pfizer, Inc.  
Pfizer, Ltd.  
PharmaNet Development Group, Inc.  
Pharming  
Phenomenome  
Discoveries, Inc.  
Philip Morris Products SA  
Philips Research Asia  
Popper & Co.  
PrecisionMed  
Predictive Biosciences  
Prensa Libre  
Pressure BioSciences  
Primorigen Biosciences  
Prisma Corp.  
ProFACT Proteomics, Inc.

Pronota NV  
Protagen AG  
Proteogenex  
Proteolix  
Proteome Sciences Plc  
Proteome Sciences R&D  
Prous Science  
Prous Science Publishers  
Quest Pharmaceutical Services  
Quinta Analytica  
Quintiles, Ltd.  
Regeneron  
Pharmaceuticals, Inc.  
Resolvix Pharmaceuticals, Inc.  
Rhode Island Hospital  
Roche Diagnostics  
Rules Based Medicine, Inc.  
San Francisco General Hospital  
Sanofi Aventis Deutschland GmbH  
sanofi aventis Group  
Sartorius North America, Inc.  
Sartorius Stedim Biotech  
SDG Life Sciences, a Unit of IMS  
SensiGen LLC  
Seoul National Univ.  
Sepracor, Inc.  
Shionogi & Co., Ltd.  
Shire Pharmaceuticals  
Signet Healthcare Partners  
Southern Medical Univ.  
St. Paul's Hospital  
Statens Serum Institut  
Strategic Diagnostics, Inc.  
SuperArray Bioscience  
Surface Logix, Inc.  
Synexa Life Sciences  
Takeda Pacific  
Takeda Pharmaceutical Co., Ltd.  
TcLand Expression  
Teva Pharmaceutical Industries  
Texas Heart Institute  
Texas Southern Univ.  
Theranostics Health  
Thermo Fisher Scientific, Inc.  
Thomson Reuters  
TNO Quality of Life  
Transgenomic, Inc.  
Trillion Genomics  
Univ. of Athens  
Univ. of Central Florida  
Univ. of Dundee  
Univ. of Florida Alachua  
Univ. of Lisboa  
Univ. of Medicine & Pharmacy  
Univ. of Nantes  
Univ. of Navarra  
Univ. of Pennsylvania  
Univ. of Texas Houston  
Univ. of the Free State  
Univ. of Victoria  
Veeda Clinical Research, Ltd.  
Veridex LLC  
VIMAC Ventures  
Waban Software  
Wayne State Univ.  
Windber Research Institute  
Wistar Institute  
World Courier  
World Courier, Inc.  
Worldwide Clinical Trials  
Wyeth Pharmaceuticals  
Wyeth Research Labs  
Xceed Molecular  
XenoBiotic Labs, Inc.  
XOMA US LLC

## Biomarker World Congress 2008

attracted 470 delegates  
from 280 companies  
and 26 countries!

# Coming Soon!

## Bio>marker BRIDGE

An interactive collaborative network community for pharmaceutical, clinical and IT professionals who are interested in gaining and sharing knowledge about technologies, research, and regulatory issues around life science.

Join and become a member of the Biomarker Bridge - enrollment opens soon!

First 200 charter members will receive a complimentary subscription to Biomarkers in Medicine

- Create a personal profile
- Browse the membership library
- Complimentary access to CHI Biomarker Events and Webinars\*
- Search continually updated Speaker Abstracts White Paper and Poster library
- Network with your peers through Forums, Blogs and Polls
- View continually updated Biomarker News
- Receive on-line access to life sciences publications

*\* Membership level determines access*

### Membership Options:

There are several different types of membership access to the Biomarker Bridge. Members to the Biomarker Bridge are granted access to a password-protected web site filled with information, tools and files specifically for Biomarker Bridge members.

Interact with your peers and engage in member-driven research, presentations, webinars and more.



***The BEST decision you will make in 2009***

***[www.biomarkerbridge.com](http://www.biomarkerbridge.com)***

If you have questions, comments or suggestions for the Biomarker Bridge, email:

**[biomarkerbridge@healthtech.com](mailto:biomarkerbridge@healthtech.com)**

**Biomedical Research Initiative Discussion Groups for Excellence**



**Cambridge Healthtech Institute**

YES! Register me for BIOMARKER WORLD CONGRESS 2009

945 F

## REGISTRATION INFORMATION

Mr.  Ms.  Mrs.  Dr.  Prof.

Mr.  Ms.  Mrs.  Dr.  Prof.

Name \_\_\_\_\_

Job Title \_\_\_\_\_ Div./Dept. \_\_\_\_\_

Company \_\_\_\_\_

Address \_\_\_\_\_

City/State/Postal Code \_\_\_\_\_

Country \_\_\_\_\_

Telephone \_\_\_\_\_

Fax \_\_\_\_\_

Email\* \_\_\_\_\_

\*Email is not a mandatory field. However, by excluding your email you will not receive notification about online access to pre-conference presenter materials, conference updates and networking opportunities.

How would you prefer to receive notices from CHI: EMAIL:  Yes  No FAX:  Yes  No

Commercial  Academic, Govt.,  
Hospital-Affiliated

### Pre-Conference Events (May 27)

Pre-Conference Executive ThinkTank (12-3pm)  Complimentary with Premium Package  
*Participation limited to senior managers at big Pharmaceutical, diagnostic or biotechnology companies All participants are subject to approval by the conference Organizers. Premium Package registration required.*

### Short Course and Tutorial Pricing

Single Short Course or Workshop	<input type="checkbox"/> \$595	<input type="checkbox"/> \$295
Short Course and Workshop	<input type="checkbox"/> \$995	<input type="checkbox"/> \$495
<i>Required-Please select the tutorial and/or workshop you will attend</i>		
Morning Workshop (8-11am)	Afternoon Short Course (12-3pm)	
<input type="checkbox"/> Biomarkers for Cancer Drug Development	<input type="checkbox"/> Fit-for-Purpose Biomarker Assay Development & Validation	

### MAIN CONFERENCE

*Standard Package: The Standard Package includes access to all Plenary Sessions, Exhibit Hall functions, and conference proceedings.*

Early Registration Discount until February 27, 2009	<input type="checkbox"/> \$1495	<input type="checkbox"/> \$595
Advance Registration Discount until April 10, 2009	<input type="checkbox"/> \$1695	<input type="checkbox"/> \$695
Registration after April 10, 2009 and on-site	<input type="checkbox"/> \$1895	<input type="checkbox"/> \$795

### Premium Package

*(Qualified Attendance only):*

The Premium Package includes access to all Plenary Session and Pre-Conference Executive ThinkTank. Access is limited to delegates who are Senior Management-level or above at pharmaceutical, diagnostic or biotechnology companies. Every registration application is subject to approval by conference organizers. For additional information, please contact Julia Boguslavsky at [juliab@healthtech.com](mailto:juliab@healthtech.com)

Early Registration Discount until February 27, 2009	<input type="checkbox"/> \$2195
Advance Registration Discount until April 10, 2009	<input type="checkbox"/> \$2395
Registration after April 10, 2009 and on-site	<input type="checkbox"/> \$2695

Poster Discount  - \$50  - \$50

## Bio>marker BRIDGE

- I am a member of the **Biomarker Bride Community Network**
- I would like receive information about the **Biomarker Bridge Community Network**

*Click here or contact Bethany Gray at 781-972-5494 - [biomarkerbridge@healthtech.com](mailto:biomarkerbridge@healthtech.com) for more informaton*

I cannot attend but would like to purchase the Biomarker World Congress 2009 conference CD's for \$500 (plus shipping).  
Massachusetts delivery will include 5% sales tax.

Please send information on exhibiting and opportunities to present workshops.

### PAYMENT INFORMATION

Enclosed is a check or money order payable to Cambridge Healthtech Institute, drawn on a U.S. bank, in U.S. currency.

Invoice me, but reserve my space with credit card information listed below.

**Invoices unpaid two weeks prior to conference will be billed to credit card at full registration rate. Invoices must be paid in full and checks received by the deadline date to retain registration discount. If you plan to register on site, please check with CHI beforehand for space availability.**

Please charge:  AMEX (15 digits)  Visa (13-16 digits)  MasterCard (16 digits)

Card # \_\_\_\_\_ Exp. Date \_\_\_\_\_

Cardholder \_\_\_\_\_

Signature \_\_\_\_\_

Cardholder's Address (if different from above) \_\_\_\_\_

City/State/Postal Code \_\_\_\_\_ Country \_\_\_\_\_

### Fax or Mail Registration to:

**CHI Cambridge Healthtech Institute**

250 First Avenue, Suite 300, Needham, MA 02494

T: 781.972.5400 • Toll-free in the U.S. 888.999.6288

F: 781.972.5425 • [www.healthtech.com](http://www.healthtech.com)

### Please send information about related CHI conferences:

- Personalized Medicine GVR
- Biomarker Assay Development BMA
- Protein Biomarkers BMK
- Clinical Biomarkers BMD

### PRESENT A POSTER AND SAVE \$50

Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. To secure a poster board and inclusion in the conference CD, your abstract must be submitted, accepted and registration paid in full by **April 15, 2009**. Register online to use the Poster Abstract Submission form or, if you register by phone, fax, or mail, you will receive Poster Abstract Submission guidelines via email. I am interested in presenting a poster at:

BIOMARKER WORLD CONGRESS and will submit a completed one-page abstract by **April 15, 2009**. (Please Note: Registration must be paid in full to present a poster.)

Title \_\_\_\_\_  
\_\_\_\_\_

### CHI Insight Pharma Reports

A series of reports that evaluate the salient trends in pharmaceutical technology, business, and therapy markets. Keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. For a list of reports, visit [InsightPharmaReports.com](http://InsightPharmaReports.com), or contact Rose LaRaia, [rlaraia@healthtech.com](mailto:rlaraia@healthtech.com), 781-972-5444.

### Barnett Educational Services

Live and web seminars, customized training, and publications for professionals involved in the drug development and clinical trials industry. Visit [www.barnettinternational.com](http://www.barnettinternational.com).

### Additional Registration Details

Each registration includes all conference sessions, posters and exhibits, food functions, and a copy of the conference CD.

### Group Discounts

Special rates are available for multiple attendees from the same organization. Contact David Cunningham at 781-972-5472 to discuss your options and take advantage of the savings.

### Handicapped Equal Access

In accordance with the ADA, Cambridge Healthtech Institute is pleased to arrange special accommodations for attendees with special needs. All requests for such assistance must be submitted in writing to CHI at least 30 days prior to the start of the meeting.

### Substitution/Cancellation Policy

In the event that you need to cancel a registration, you may:

- Transfer your registration to a colleague within your organization. Credit your registration to another Cambridge Healthtech Institute program.
- Request a refund minus a \$100 processing fee per conference.
- Request a refund minus the cost (\$500) of ordering a copy of the CD.

NOTE: Cancellations will only be accepted up to two weeks prior to the conference. Program and speakers are subject to change.

Video and/or audio recording of any kind is prohibited onsite at all CHI events.

CAMBRIDGE HEALTHTECH INSTITUTE OFFERS AN EXPANSIVE SUITE of information resources specific to Biomarkers and Diagnostics. Follow these links for articles, social networking, research, seminars and conferences all pertaining to Biomarkers and Diagnostics.

## Bio-IT World

Technologies Driving Discovery, Development, and Clinical Trials

### Insights on Biomarkers and Diagnostics



*Bio-IT World* magazine – CHI's flagship publication – publishes critical insight, analysis, and opinion on the tools and results of predictive biology, drug discovery,

informatics, clinical research, and personalized medicine, in addition to the strategic decisions made by companies in these areas. Please visit [www.bio-itworld.com](http://www.bio-itworld.com) to view feature articles, white papers, and podcasts on the life sciences industry and to subscribe to the magazine.

A series of insightful and informative articles focusing on Biomarkers and Diagnostics are below. Please click on each article link to read.

■ **Using Molecular Diagnostics**

*By Larry Hand*

■ **Amgen's Personalized Medicine Story**

*By Kevin Davies, Ph.D.*

■ **The Biomarker Business**

*By Christopher Huels*

■ **Merck-Moffitt Partnership Breaks Down Silos**

*By Catherine Varmazis*

■ **Dutch Drug Development Heats Up**

*By Allison Proffitt*

#### Related Web Site

Introducing [www.eCliniqua.com](http://www.eCliniqua.com) – a web site focusing on the clinical trials industry.

**STAY INFORMED** with free eNewsletters focusing on the life sciences industry from Cambridge Healthtech Media group - [www.chimedialog.com](http://www.chimedialog.com).

The latest industry news, commentary and highlights from Bio-IT World.

#### eCliniqua

Innovative management in clinical trials.

#### Predictive Biomedicine

Informatics tools and strategies driving decisions.

## CHI's Biomarker Series: Six Years of Success



CHI's Biomarker Series features several biomarker related events annually, attracting upwards of 500 participants. Due to an overwhelming response from the scientific community and a consistent track-record of delivering cutting-edge programs and an expert audience, this series has shown a positive growth and has branched out to include coverage in Translational Medicine, Biomarker Assay Development, Personalized Medicine, Oncology, and Clinical Pharmacology to name a few. In order to bring you the solutions and strategies that impact the bottom line, as well as provide a forum to address the most timely opportunities and the most burning issues industry-wide, we spent years researching the issues pertaining to biomarker implementation and staying in close contact with pharmaceutical executives and leading scientists. We believe that the potential value of biomarkers can best be exploited by working together and sharing information. We invite you to join us in this process. The Biomarker Series flag ship event is the Fifth Annual Biomarker World Congress, to be held May 27-29, 2009 in Philadelphia. This event features more than 500 attendees, 30 exhibits, 60 presentations and numerous networking opportunities.

- **The Biomarker World Congress**
- **Biomarker Assay Development**
- **Translational Cancer Medicine**
- **Translational Medicine**
- **Biomarker Discovery Summit**
- **Biomarkers Europe**
- **ADAPT**
- **Protein Biomarkers**

## Biomarker BRIDGE

### What is the Biomarker Bridge?


An interactive collaborative network community for pharmaceutical, clinical and IT professionals who are interested in gaining and sharing knowledge about technologies, research, and regulatory issues around life science. ■ **Sign up today!**

### Insight Pharma Reports

## Insight Pharma Reports Targets Cardiotoxicity and Biomarker SOPs

Insight Pharma Reports is the premier life science information provider. Insight Pharma Reports offer unparalleled coverage of key issues in biomarkers and diagnostics. Our reports are used by leading pharmaceutical, biotech, diagnostic, and other life science companies to keep abreast of the latest developments in pharmaceutical R&D and their potential applications and business impacts. The reports are written by experts in consulting and industry, and are supported by hundreds of hours of primary and secondary research.

- **Molecular Diagnostics: A Dynamic and Rapidly Broadening Market**
- **Cancer Biomarkers: Adoption Is Driving Growth**
- **Disease-Related Biomarkers: Their Potential in Patient Screening, Prognosis, and Stratification**
- **Biomarker SOPs: Getting Optimum Value from Your Biomarker Programs**
- **Biomarkers in Clinical Development: Implications for Personalized Medicine and Streamlining R&D**



## Barnett Seminars Keep You Informed on the Latest in Biomarkers and Diagnostics Issues

CHI's Barnett International is the premier provider of clinical research training resources. Through its live courses, web-based training, eLearning, and in-house training and consulting services, and publications, Barnett partners with leading sponsors, CROs and clinical research sites to ensure that research teams are trained according to FDA, ICH and global regulatory standards. Featured events and services include:

- **Biomarkers of Drug Efficacy and Safety Training**
- **Clinical Trials for Pharmaceuticals: Design and Development**
- **Adverse Events: Managing and Reporting for Pharmaceuticals**
- **Curriculum Compliance Assessment and Development**



The Drug Safety Executive Council (DSEC) is a peer-to-peer membership of over 1,500 drug safety leaders with the common objective of advancing the development of better and safer medicines.